United States securities and exchange commission logo





                              May 22, 2020

       William M. Haskel
       Senior Vice President, General Counsel and Corporate Secretary
       Paratek Pharmaceuticals, Inc.
       75 Park Plaza
       Boston, MA 02116

                                                        Re: Paratek
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed May 11, 2020
                                                            File No. 333-238150

       Dear Mr. Haskel:

               We have limited our review of your registration statement to the
issues we have
       addressed in our comment. Please respond to this letter by amending your
registration statement
       and providing the requested information. If you do not believe our
comment applies to your
       facts and circumstances or do not believe an amendment is appropriate,
please tell us why in
       your response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to our comment, we may have additional comments.

       Form S-3 filed May 11, 2020

       General

   1.                                                   We note that Section 48
of your bylaws includes a forum selection provision which
                                                        identifies the Court of
Chancery of the State of Delaware as the exclusive forum for
                                                        certain litigation,
including "any derivative action." Please revise your prospectus to
                                                        clearly describe any
risks or other impacts on investors. Please also disclose whether this
                                                        provision applies to
actions arising under the Securities Act or Exchange Act. In that
                                                        regard, we note that
Section 27 of the Exchange Act creates exclusive federal jurisdiction
                                                        over all suits brought
to enforce any duty or liability created by the Exchange Act or the
                                                        rules and regulations
thereunder, and Section 22 of the Securities Act creates concurrent
                                                        jurisdiction for
federal and state courts over all suits brought to enforce any duty or
                                                        liability created by
the Securities Act or the rules and regulations thereunder. If the
                                                        provision applies to
Securities Act claims, please also revise your prospectus to state that
                                                        there is uncertainty as
to whether a court would enforce such provision and that investors
                                                        cannot waive compliance
with the federal securities laws and the rules and regulations
 William M. Haskel
Paratek Pharmaceuticals, Inc.
May 22, 2020
Page 2
         thereunder. If this provision does not apply to actions arising under
the Securities Act or
         Exchange Act, please tell us how you will inform investors in future
filings that the
         provision does not apply to any actions arising under the Securities
Act or Exchange Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Abby Adams at (202) 551-6902 or Joseph McCann at (202)
551-6262 with
any questions.



FirstName LastNameWilliam M. Haskel                            Sincerely,
Comapany NameParatek Pharmaceuticals, Inc.
                                                               Division of
Corporation Finance
May 22, 2020 Page 2                                            Office of Life
Sciences
FirstName LastName